

Premarket Approval (PMA) Submissions Workshop

AdvaMed Office

1301 Pennsylvania Ave. N.W. Suite 400 Washington, D.C. February 8 – 9, 2024

Feb 8, 2024

8:30 – 9:00 am Registration Check-In and Continental Breakfast

9:00 – 9:05 am Welcome and Introductions

9:05 – 10:00 am Beginning at the Beginning

Quynh Hoang, Senior Regulatory Consultant, FDA and Life Science Practice, King & Spalding

- When is a De Novo or PMA required
- PMA: what to expect
 - What are the standards of evidence
 - What are the standards of review
 - Will submission go to panel
 - o How much will it cost
 - How long will it take to get approval

10:00 – 10:45 am Development of a PMA Submission Strategy

Stacy Monza, FDA

- Product definition
 - Development of testing requirements and strategy
 - Desired patient population
 - Desired claims
 - Early interactions with FDA
 - Planning for product iterations

10:45 - 11:00 am Break

11:00 – 12:00 pm Mechanics of PMA Quality System Submission Development and Review

Jhumur Banik, FDA

- Defining data requirements
- Required elements
- Presentation of information with clarity
- Expectations during review
- Best practices
- Manufacturing & Quality Systems
- Case for Quality

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



12:00 - 1:00 pm

Networking Lunch

1:00 - 2:00 pm

During Submission Review

Jennifer Bolton, Senior Fellow, Regulatory Affairs, Boston Scientific

- Interactions with the FDA
- When/How to expect questions
- Types of letters
- Timelines
- Day 100 meetings
- Labeling review

2:00 - 3:00 pm

Conditions of Approval Studies

Jennifer Bolton, Senior Fellow, Regulatory Affairs, Boston Scientific

- · Criteria and objectives
- Early collaboration with FDA
- · Reaching agreement
- Reporting outcomes
- 522 Studies

3:00 - 3:15 pm

Break

3:15 - 4:15 pm

Preparation for Advisory Panels

Jessica Ringel, Partner, King & Spalding

- When?
- Who are the panel members?
- Why have a panel meeting?
- · Preparation for a panel meeting
- What to expect before, during, and after
- Best practices

4:15 - 5:15 pm

Networking Reception



Feb. 9, 2024

8:30 – 9:00 am Continental Breakfast

9:00 – 10:00 am Inspection Activity

Jacob Dyer, FDA

Pre-approval inspections

How to prepare for an inspection

10:00 – 11:00 am Dealing with the Unexpected

Tony Blank, Senior Director of Regulatory Affair, AtriCure

Clinical outcomes

Animal test results

Adverse panel recommendation

11:00 - 11:15 am Break

11:15 am – 12:15 pm The Care and Feeding of Approved PMAs

Monica Montanez, Principal Strategy Consultant, NAMSA

• Periodic ("Annual") Reports

Supplemental Submissions

30-day notices

12:15 – 1:15 pm Networking Lunch

1:15 – 2:00 pm CDRH Ombudsman's Office

Ken Skodacek, FDA

Roles & Responsibilities

The Appeals Process

2:00 - 2:15 pm Break

2:15 – 4:15 pm Applied Learning and Breakout Discussions

Tony Blank, Senior Director of Regulatory Affair, AtriCure

PMA Recap

Facilitated Breakout Group Deep Dive

Hypothetical Case Studies

Key Takeaways

Regroup for Final Program Q&A

4:15 pm Adjournment

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.